TILDA: A new sensitive and precise assay to measure the size of the latent HIV reservoir

TILDA：一种新的灵敏且精确的检测方法，用于测量潜在 HIV 病毒库的大小

• 批准号: 8880118
• 负责人: Nicolas Chomont
• 金额: $ 16.2万
• 依托单位: UNIVERSITY OF MONTREAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-01-01 至 2017-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8880118
• 关键词: Acetates; Acute; Anti-Retroviral Agents; Biological Assay; Blood; CD4 Positive T Lymphocytes; Cell Count; Cells; Chronic; Clinical; Clinical Trials; Cohort Studies; DNA; DNA biosynthesis; Defective Viruses; Frequencies; Genome; Goals; Gold; HIV; HIV Infections; Health; Human; Individual; Infection; Interruption; Ionomycin; Laboratories; Life; Measurement; Measures; Memory; Methods; Names; Nucleic Acids; Pharmaceutical Preparations; Procedures; Production; Proviruses; RNA; RNA Splicing; Relative (related person); Research Project Grants; Rest; Source; Staging; Surrogate Markers; T-Lymphocyte Subsets; Testing; Therapeutic; Time; Transcript; Variant; Viral; Viral Genome; Viremia; Virion; Virus; antiretroviral therapy; base; innovation; memory CD4 T lymphocyte; novel; particle; phorbol-12-myristate

DESCRIPTION (provided by applicant): It is now clear that antiretroviral therapy (ART) alone does not eradicate HIV: Even after more than 15 years of intensive and continuous therapy, the spread of the virus resumes within a few weeks upon cessation of ART in all but exceptional cases. In virally suppressed subjects, only about one in a million resting CD4+ T cells contain latent proviruses capable of producing replication-competent virus. Quantifying cells harboring latent HIV is critical to evaluating strategies to eliminate them, but the low frequency of these cells makes this extremely challenging. With an increasing number of novel and innovative therapeutic strategies that will be tested in humans to reduce the size of the latent reservoir, there is an urgent need to develop a robust, precise and clinical trial scalable assay that measures the frequency of latently cells infected cells carrying inducible HIV. We have recently developed an assay to measure the magnitude of the latent -and inducible- HIV reservoir, which will fulfill these criteria. This novel assay, named TILDA for Tat/rev Induced Limiting Dilution Assay, measures the frequency of cells with multiply spliced HIV RNA upon maximal cellular activation with PMA/ionomycin. Importantly, our assay does not require extraction of viral nucleic acids, which makes TILDA suitable for high throughput studies. TILDA requires only 10mL of blood, is extremely reproducible (coefficient of variation = 0.2), covers a wide dynamic range of reservoir size (over 3 logs) and can be completed in two days. The objective of this proposal is to demonstrate that TILDA can be used to precisely measure the frequency of latently infected cells that persist in virally suppressed subjects. We will use TILDA to measure the size of the reservoir in 36 subjects on suppressive ART and will correlate these values with those measured by the gold standard method (quantitative viral outgrowth assay, Q-VOA) in two laboratories with strong expertise in this assay (Dr. Siliciano and Dr. Markowitz, collaborators). In Specific Aim 1, we will determine if the frequency of reservoir cells measured by TILDA correlates with those measured by Q-VOA. We hypothesize that these frequencies will correlate, but that TILDA will provide a better estimate of the size of the pool of latently infectd cells. In Specific Aim 2, we will use TILDA to assess the relative proportion of cells with integrated HIV DNA that can be induced to produce HIV in subjects who started ART during the acute and the chronic stages of HIV infection. We predict that a large fraction of the integrated genomes will not be inducible in individuals who started ART during chronic infection. In Specific Aim 3, we will use TILDA to measure the size of the latent HIV reservoir in distinct memory CD4 T cell subsets, with the hypothesis that the more differentiated subsets (effector memory cells) will carry a larger proportion of defective viruses. The overarching goal of this project is to demonstrate that TILDA can be used universally in a clinical setting to precisely measure the size of the latent reservoir and assess the efficacy of eradication strategies.

描述(申请人提供)：现在很明显，单靠抗逆转录病毒疗法(ART)并不能根除艾滋病毒：即使经过15年以上的密集和持续治疗，病毒的传播在停止ART后的几周内都会恢复，但在特殊情况下除外。在病毒抑制的受试者中，只有大约百万分之一的静止的CD4+T细胞含有能够产生复制能力的病毒的潜伏前病毒。量化携带潜伏艾滋病毒的细胞对于评估消除它们的策略至关重要，但这些细胞的低频率使这一点极具挑战性。随着越来越多的新的和创新的治疗策略将在人体上进行测试，以减少潜伏的宿主的大小，迫切需要开发一种强大、准确和临床试验可扩展的检测方法，以测量携带可诱导的HIV的潜伏细胞感染细胞的频率。我们最近开发了一种测试方法来测量潜伏的和可诱导的艾滋病毒储备库的大小，这将满足这些标准。这种新的检测方法名为Tilda，即TAT/REV诱导的限制性稀释实验，它测量了在PMA/离子霉素最大限度地激活细胞时，含有多剪接HIV RNA的细胞的频率。重要的是，我们的检测不需要提取病毒核酸，这使得Tilda适合高通量研究。Tilda只需要10毫升血液，重复性极好(变异系数=0.2)，涵盖了储油罐大小的广泛动态范围(超过3个对数)，可以在两天内完成。这项建议的目的是证明Tilda可以用来精确测量潜伏感染细胞在病毒抑制的受试者中持续存在的频率。我们将使用Tilda来测量36名抑制ART受试者的储存池大小，并将这些值与金标准方法(定量病毒生长试验，Q-VOA)在两个实验室(合作者西里西亚诺博士和马科维茨博士)中测量的结果相关联。在具体目标1中，我们将确定Tilda测量的水库细胞频率是否与Q-VOA测量的频率相关。我们假设这些频率将相互关联，但Tilda将更好地估计潜伏感染细胞池的大小。在具体目标2中，我们将使用Tilda来评估在HIV感染的急性和慢性阶段开始抗逆转录病毒治疗的受试者中，整合了HIV DNA的细胞可以被诱导产生HIV的相对比例。我们预测，在慢性感染期间开始抗逆转录病毒治疗的个体中，很大一部分整合的基因组将不会被诱导。在具体目标3中，我们将使用Tilda来测量不同记忆CD4T细胞亚群中潜伏的HIV储存库的大小，假设分化程度较高的亚群(效应器记忆细胞)将携带更大比例的缺陷病毒。该项目的主要目标是证明Tilda可在临床环境中普遍使用，以准确测量潜在储存库的大小，并评估根除策略的有效性。